Atebimetinib

Atebimetinib is a small-molecule drug developed by Immuneering. Its target is MEK1/2 (the sponsor names MEK). The sponsor states: Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07562152, plans to enrol 510 participants with primary completion expected 2028-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.